{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:27:25Z","timestamp":1792661245480,"version":"4.5.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.vaccine.2015.11.062","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T17:50:23Z","timestamp":1450374623000},"page":"413-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":254,"title":["Prime-boost vaccine strategy against viral infections: Mechanisms and benefits"],"prefix":"10.1016","volume":"34","author":[{"given":"Kimia","family":"Kardani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Bolhassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.11.062_bib0650","first-page":"218590","article-title":"Emerging vaccine informatics","volume":"2010","author":"He","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"34","key":"10.1016\/j.vaccine.2015.11.062_bib0655","doi-asserted-by":"crossref","first-page":"12313","DOI":"10.1073\/pnas.1400475111","article-title":"Valuing vaccination","volume":"111","author":"B\u00e4rnighausen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib0660","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0665","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/BA20000034","article-title":"Design and production of recombinant subunit vaccines","volume":"32","author":"Hansson","year":"2000","journal-title":"Biotechnol Appl Biochem"},{"issue":"45","key":"10.1016\/j.vaccine.2015.11.062_bib0670","first-page":"1","article-title":"Combined prime-boost vaccination against tick-borne encephalitis (TBE), using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein","volume":"5","author":"Aleshin","year":"2005","journal-title":"BMC Microbiol"},{"issue":"494","key":"10.1016\/j.vaccine.2015.11.062_bib0675","first-page":"1","article-title":"DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB\/c mice","volume":"13","author":"Meng","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.062_bib0680","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"10.1016\/j.vaccine.2015.11.062_bib0685","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.062_bib0695","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0700","first-page":"422","article-title":"Application of prime-boost as a novel vaccination strategy against microbial pathogens","author":"Gaspari","year":"2011","journal-title":"FORMATEX"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib0705","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.it.2003.11.009","article-title":"Jump-starting the immune system: prime-boosting comes of age","volume":"25","author":"Woodland","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0710","series-title":"Heterologous prime-boost immunization regimens against infectious diseases","first-page":"1","author":"Shahin","year":"2006"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0715","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1242\/jeb.00642","article-title":"Prime-boost strategies for malaria vaccine development","volume":"206","author":"Dunachie","year":"2003","journal-title":"J Exp Biol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0720","series-title":"Heterologous prime-boost immunization in Ebola vaccine development, testing and licensure","first-page":"1","author":"Moorthy","year":"2014"},{"issue":"7","key":"10.1016\/j.vaccine.2015.11.062_bib0725","first-page":"1","article-title":"Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen","volume":"7","author":"Alekseeva","year":"2009","journal-title":"Genet Vacc Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.062_bib0730","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.4049\/jimmunol.170.5.2599","article-title":"Prime-boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias","volume":"170","author":"Woodberry","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.062_bib0735","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-5699(00)01612-1","article-title":"The prime-boost strategy: exciting prospects for improved vaccination","volume":"21","author":"Ramshaw","year":"2000","journal-title":"Trends Immunol Today"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0740","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/eji.200839167","article-title":"Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay","volume":"39","author":"Winstone","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0745","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1128\/IAI.00590-06","article-title":"A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge","volume":"74","author":"Dunachie","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0750","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.062_bib0755","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/infdis\/jit267","article-title":"A heterologous prime\/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for Hepatitis C virus","volume":"208","author":"Fournillier","year":"2013","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib0760","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vacc"},{"issue":"10","key":"10.1016\/j.vaccine.2015.11.062_bib0765","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1128\/JVI.80.10.4717-4728.2006","volume":"80","author":"Goonetilleke","year":"2006","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.062_bib0770","doi-asserted-by":"crossref","first-page":"e0118486","DOI":"10.1371\/journal.pone.0118486","article-title":"Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults","volume":"10","author":"Joachim","year":"2015","journal-title":"PLOS ONE"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2015.11.062_bib0775","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","article-title":"Therapeutic HPV DNA vaccines","volume":"47","author":"Lin","year":"2010","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.062_bib0780","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11262-014-1070-z","article-title":"Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime\/lambda nanoparticles boost in mice","volume":"49","author":"Saeedi","year":"2014","journal-title":"Virus Genes"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0785","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.vaccine.2008.04.073","article-title":"DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib0790","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1093\/infdis\/jiv175","article-title":"Optimization of prime-boost vaccination strategies against mouse-adapted ebola virus in a short-term protection study","volume":"212","author":"Aviles","year":"2015","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.062_bib0795","doi-asserted-by":"crossref","first-page":"e2600","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus","volume":"7","author":"Mire","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2015.11.062_bib0800","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0684.2005.00120.x","article-title":"Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate","volume":"34","author":"Pal","year":"2005","journal-title":"J Med Primatol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2015.10.012","article-title":"Prime\/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses","author":"Bolhassani","year":"2015","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0810","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/j.vaccine.2008.03.082","article-title":"Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies","volume":"26","author":"Bolhassani","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0815","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.micpath.2015.07.008","article-title":"Protective effects of recombinant glycoprotein D based prime boost approach against duck enteritis virus in mice model","volume":"88","author":"Aravind","year":"2015","journal-title":"Microb Pathog"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.062_bib0820","doi-asserted-by":"crossref","first-page":"e0122835","DOI":"10.1371\/journal.pone.0122835","article-title":"Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-cell responses in Macaques","volume":"10","author":"Lorin","year":"2015","journal-title":"PLOS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2015.11.062_bib0825","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.03574-13","article-title":"Combined adenovirus vector and Hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses","volume":"88","author":"Chmielewska","year":"2014","journal-title":"J Virol"},{"issue":"32","key":"10.1016\/j.vaccine.2015.11.062_bib0830","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1016\/j.vaccine.2007.05.052","article-title":"DNA-VLP prime-boost intranasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity","volume":"25","author":"Buonaguro","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0835","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pep.2015.08.024","article-title":"VLP production in Leishmania tarentolae: a novel expression system for purification and assembly of HPV16 L1","volume":"116","author":"Bolhassani","year":"2015","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0840","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1128\/JVI.75.13.5879-5890.2001","article-title":"Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques","volume":"75","author":"Montefiori","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0845","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0264-410X(02)00773-9","article-title":"Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime\u2013boost vaccination protocols against SHIV","volume":"21","author":"Radaelli","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/femspd\/ftu012","article-title":"An effective DNA priming-protein boosting approach for the cervical cancer vaccination","volume":"73","author":"Kianmehr","year":"2015","journal-title":"Pathog Dis"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0855","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1128\/IAI.73.7.4441-4444.2005","article-title":".The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins Hsp65, Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis","volume":"73","author":"Skinner","year":"2005","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.062_bib0860","first-page":"1","article-title":"Is prime-boost strategy a promising approach in HIV vaccine development?","volume":"5","author":"Shete","year":"2014","journal-title":"J AIDS Clin Res"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0865","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0870","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00042560-200203010-00005","article-title":"Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A","volume":"29","author":"Gupta","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0875","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0880","first-page":"1","article-title":"Human immunodeficiency virus vaccine trials","volume":"2","author":"O\u2019Connell","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"20","key":"10.1016\/j.vaccine.2015.11.062_bib0885","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib0890","article-title":"Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083)","author":"Walsh","year":"2015","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2015.11.062_bib0895","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1172\/JCI75894","article-title":"HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial","volume":"124","author":"Bart","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.vaccine.2015.11.062_bib0900","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.03574-13","article-title":"Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses","volume":"88","author":"Chmielewska","year":"2014","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.11.062_bib0905","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/ijc.27640","article-title":"Therapeutic live vaccines as a potential anti-cancer strategy","volume":"131","author":"Bolhassani","year":"2012","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.vaccine.2015.11.062_bib0910","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/imt.12.110","article-title":"Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model","volume":"4","author":"Salehi","year":"2012","journal-title":"Immunotherapy"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2015.11.062_bib0915","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/10717544.2013.801534","article-title":"A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers","volume":"20","author":"Hosseinzadeh","year":"2013","journal-title":"Drug Deliv"},{"issue":"8","key":"10.1016\/j.vaccine.2015.11.062_bib0920","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1099\/vir.0.79869-0","article-title":"Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime\/MVA boost vaccine regimen","volume":"85","author":"Makitalo","year":"2004","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2015.11.062_bib0925","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.4049\/jimmunol.172.10.6209","article-title":"Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule","volume":"172","author":"Gherardi","year":"2004","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.vaccine.2015.11.062_bib0930","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1128\/JVI.78.14.7490-7497.2004","article-title":"Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys","volume":"78","author":"Letvin","year":"2004","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.vaccine.2015.11.062_bib0935","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1128\/JVI.77.16.8729-8735.2003","article-title":"Plasmid chemokines and colony stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines","volume":"77","author":"Barouch","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.062_bib0940","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virusres.2004.04.008","article-title":"Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime\/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma","volume":"105","author":"Gomez","year":"2004","journal-title":"Virus Res"},{"issue":"7","key":"10.1016\/j.vaccine.2015.11.062_bib0945","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/00002030-200404300-00006","article-title":"Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime\/protein boost regimen","volume":"18","author":"Leung","year":"2004","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib0950","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1099\/vir.0.19396-0","article-title":"Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice","volume":"85","author":"Jaffray","year":"2004","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.062_bib0955","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1099\/vir.0.18589-0","article-title":"Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate DSTO-GD-047413 (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost","volume":"84","author":"Vinner","year":"2003","journal-title":"J Gen Virol"},{"issue":"19\u201320","key":"10.1016\/j.vaccine.2015.11.062_bib0960","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0264-410X(03)00099-9","article-title":"Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming","volume":"21","author":"Wang","year":"2003","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.062_bib0965","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.4049\/jimmunol.171.12.6774","article-title":"Induction of CD8+ T cells to an HIV-1 antigen through a prime-boost regimen with heterologous E1-deleted adenoviral vaccine carriers","volume":"171","author":"Pinto","year":"2003","journal-title":"J Immunol"},{"issue":"17","key":"10.1016\/j.vaccine.2015.11.062_bib0970","doi-asserted-by":"crossref","first-page":"9378","DOI":"10.1073\/pnas.94.17.9378","article-title":"Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination","volume":"94","author":"Letvin","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.vaccine.2015.11.062_bib0975","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.4049\/jimmunol.173.11.7078","article-title":"Intranasal HIV-1-gp160-DNA\/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity","volume":"173","author":"Devito","year":"2004","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.vaccine.2015.11.062_bib0980","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.vaccine.2004.10.030","article-title":"Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy","volume":"23","author":"Stambas","year":"2005","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.062_bib0985","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.4049\/jimmunol.164.9.4968","article-title":"Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime\/modified vaccinia virus Ankara boost regimen","volume":"164","author":"Allen","year":"2000","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2015.11.062_bib0990","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/sj.gt.3302241","article-title":"Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa","volume":"11","author":"Nkolola","year":"2004","journal-title":"Gene Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2015.11.062_bib0995","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0264-410X(96)00264-2","article-title":"Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit","volume":"15","author":"Barnett","year":"1997","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.11.062_bib1000","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/BA20030176","article-title":"Modified-vaccinia-virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T-cell response in mice against an HIV-1 epitope than does a DNA\/poxvirus prime-booster approach","volume":"39","author":"Vazquez-Blomquist","year":"2004","journal-title":"Biotechnol Appl Biochem"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib1005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1099\/vir.0.18738-0","article-title":"Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine","volume":"84","author":"Hanke","year":"2003","journal-title":"J Gen Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.062_bib1010","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.4049\/jimmunol.171.5.2538","article-title":"Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses","volume":"171","author":"Tritel","year":"2003","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.062_bib1015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2004.10.018","article-title":"Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach","volume":"331","author":"Tan","year":"2005","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.062_bib1020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/BA20040065","article-title":"A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia-virus infection","volume":"41","author":"Quintana-Vazquez","year":"2005","journal-title":"Biotechnol Appl Biochem"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.062_bib1025","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1128\/JVI.77.12.7048-7057.2003","article-title":"Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes","volume":"77","author":"Gherardi","year":"2003","journal-title":"J Virol"},{"issue":"32","key":"10.1016\/j.vaccine.2015.11.062_bib1030","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1016\/j.vaccine.2007.05.052","article-title":"DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity","volume":"25","author":"Buonaguro","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.11.062_bib1035","doi-asserted-by":"crossref","first-page":"P403","DOI":"10.1186\/1742-4690-6-S3-P403","article-title":"A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA","volume":"6","author":"Bakari","year":"2009","journal-title":"Retrovirology"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.062_bib1040","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/hv.20778","article-title":"Poxvirus vectors as HIV\/AIDS vaccines in humans","volume":"8","author":"Gomez","year":"2012","journal-title":"Hum Vacc Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.062_bib1045","doi-asserted-by":"crossref","first-page":"e27837","DOI":"10.1371\/journal.pone.0027837","article-title":"Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B\/E vaccination in an efficacy trial in Thailand","volume":"6","author":"Pitisuttithum","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1050","first-page":"4","article-title":"Phase II prime-boost trial begins in the US","volume":"13","author":"McEnery","year":"2015","journal-title":"VAX"},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.062_bib1055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/1570162X113116660051","article-title":"Lessons learned from HIV vaccine clinical efficacy trials","volume":"11","author":"Day","year":"2013","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/v2020435","article-title":"Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials","volume":"2","author":"Brown","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified Vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"JID"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.062_bib1070","doi-asserted-by":"crossref","first-page":"e0119629","DOI":"10.1371\/journal.pone.0119629","article-title":"Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial","volume":"10","author":"Munseri","year":"2015","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2015.11.062_bib1075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/CVI.00637-12","article-title":"Safety and immunogenicity of DNA prime and modified Vaccinia Ankara virus-HIV subtype C vaccine boost in healthy adults","volume":"20","author":"Hayes","year":"2013","journal-title":"Clin Vacc Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.062_bib1080","doi-asserted-by":"crossref","first-page":"e84234","DOI":"10.1371\/journal.pone.0084234","article-title":"HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo","volume":"8","author":"Muthumani","year":"2013","journal-title":"PLOS ONE"},{"issue":"18","key":"10.1016\/j.vaccine.2015.11.062_bib1085","doi-asserted-by":"crossref","first-page":"9842","DOI":"10.1128\/JVI.78.18.9842-9853.2004","article-title":"A consecutive priming-boosting vaccination of mice with Simian Immunodeficiency virus (SIV) gag\/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity","volume":"78","author":"Someya","year":"2004","journal-title":"J Virol"},{"issue":"30","key":"10.1016\/j.vaccine.2015.11.062_bib1090","doi-asserted-by":"crossref","first-page":"11088","DOI":"10.1073\/pnas.0401954101","article-title":"Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses","volume":"101","author":"Santra","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.vaccine.2015.11.062_bib1095","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1128\/JVI.78.24.13819-13828.2004","article-title":"Efficacy of DNA and Fowlpox virus priming\/boosting vaccines for simian\/human immunodeficiency Virus","volume":"78","author":"Dale","year":"2004","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2015.11.062_bib1100","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1128\/JVI.77.21.11563-11577.2003","article-title":"Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after Simian-Human Immunodeficiency virus SHIV89.6P mucosal challenge","volume":"77","author":"Doria-Rose","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/viro.2001.1345","article-title":"Comparison of vaccine strategies using recombinant env\u2013gag\u2013pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model","volume":"294","author":"Earl","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1574-695X.2003.tb00649.x","article-title":"Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA\/fowlpox priming and virus-like particle boosting","volume":"35","author":"Zanotto","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1115","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0264-410X(02)00773-9","article-title":"Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV","volume":"21","author":"Radaelli","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1120","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1128\/JVI.01120-09","article-title":"Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T cell help on control of a simian immunodeficiency virus challenge in rhesus macaques","author":"Tsukamoto","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1125","first-page":"1","article-title":"Enhancement of Gag-specific but reduction of Env- and Pol- specific CD8+ T cell responses by Simian Immunodeficiency virus nonstructural proteins in mice","volume":"27","author":"Zhang","year":"2011","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization resistant SIV challenges in rhesus monkeys","volume":"482","author":"Barouch","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.062_bib1135","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1128\/JVI.02216-07","article-title":"Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates","volume":"82","author":"Mooij","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1140","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0684.1999.tb00271.x","article-title":"Immunization against SIVmne in macaques using multigenic DNA vaccines","volume":"28","author":"Mossman","year":"1999","journal-title":"J Med Primatol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.062_bib1145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.virol.2004.12.026","article-title":"DNA prime\/Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication","volume":"333","author":"Boyer","year":"2005","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.062_bib1150","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/JVI.78.5.2212-2221.2004","article-title":"Protection against mucosal Simian Immunodeficiency virus SIVmac251 challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting","volume":"78","author":"Patterson","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1155","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0264-410X(02)00781-8","article-title":"Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants","volume":"21","author":"Nakaya","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.virol.2006.05.012","article-title":"Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime\/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses","volume":"353","author":"Malkevitch","year":"2006","journal-title":"Virology"},{"issue":"5043","key":"10.1016\/j.vaccine.2015.11.062_bib1165","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1126\/science.1531159","article-title":"Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160","volume":"255","author":"Hu","year":"1992","journal-title":"Science"},{"issue":"6245","key":"10.1016\/j.vaccine.2015.11.062_bib1170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus-protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"Barouch","year":"2015","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.vaccine.2015.11.062_bib1175","doi-asserted-by":"crossref","first-page":"11891","DOI":"10.1128\/JVI.75.23.11891-11896.2001","article-title":"Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime\/Sendai virus vector boost regimen","volume":"75","author":"Matano","year":"2001","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2015.11.062_bib1180","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1128\/JVI.05060-11","article-title":"Enhanced control of pathogenic Simian Immunodeficiency virus SIVmac239 replication in macaques immunized with an Interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen","volume":"85","author":"Winstone","year":"2011","journal-title":"J Virol"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2015.11.062_bib1185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-2478(98)00164-3","article-title":"Preclinical development of a multi-CTL epitope-based DNA prime\/MVA boost vaccine for AIDS","volume":"66","author":"Hanke","year":"1999","journal-title":"Immunol Lett"},{"issue":"18","key":"10.1016\/j.vaccine.2015.11.062_bib1190","doi-asserted-by":"crossref","first-page":"10113","DOI":"10.1128\/JVI.77.18.10113-10118.2003","article-title":"Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multi-epitope DNA vaccination in rhesus monkeys","volume":"77","author":"Subbramanian","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1099\/0022-1317-83-1-75","article-title":"A DNA\/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques","volume":"83","author":"Wee","year":"2002","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.062_bib1200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/JVI.77.1.382-390.2003","article-title":"DNA immunization with Hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant Canarypox virus boosting induces immune responses and protection from recombinant HCV-Vaccinia virus infection in HLA-A2.1-transgenic mice","volume":"77","author":"Pancholi","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1205","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/infdis\/jit267","article-title":"A heterologous prime\/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for Hepatitis C virus","volume":"208","author":"Fournillier","year":"2013","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.062_bib1210","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.4049\/jimmunol.180.9.6159","article-title":"A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection","volume":"180","author":"Yang","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1215","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1086\/344234","article-title":"Prime-boost immunization with DNA and modified Vaccinia virus Ankara vectors expressing Herpes Simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone","volume":"186","author":"Meseda","year":"2002","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2015.11.062_bib1220","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0264-410X(99)00400-4","article-title":"A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in na\u00efve and infection-primed mice","volume":"18","author":"Ruitenberg","year":"2000","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2015.11.062_bib1225","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1128\/JVI.75.13.5939-5948.2001","article-title":"Immunogenicity and protective efficacy of recombinant human T-cell leukemia\/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)","volume":"75","author":"Kazanji","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.062_bib1230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1135(00)00388-6","article-title":"A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever","volume":"80","author":"Hammond","year":"2001","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1235","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1525-0016(03)00238-7","article-title":"Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles","volume":"8","author":"Lin","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1240","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12967-015-0437-9","article-title":"A prime\/boost strategy using DNA\/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV16-associated cancers","volume":"13","author":"Bissa","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1245","first-page":"1035","article-title":"Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene","volume":"60","author":"Chen","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1250","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.cgt.7700723","article-title":"DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins","volume":"11","author":"Wlazlo","year":"2004","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1255","first-page":"311","article-title":"Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2","volume":"13","author":"Rittich","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.vaccine.2015.11.062_bib1260","unstructured":"Johns Hopkins University. Vaccine therapy with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia [ClinicalTrials.gov identifier NCT00788164]. US National Institutes of Health. ClinicalTrials.gov [online]. Available from: http:\/\/www.clinicaltrials.gov [accessed 04.06.09]."},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2015.11.062_bib1265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","article-title":"Therapeutic HPV DNA vaccines","volume":"47","author":"Lin","year":"2010","journal-title":"Immunol Res"},{"issue":"3","key":"10.1016\/j.vaccine.2015.11.062_bib1270","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1525-1438.2006.00598.x","article-title":"Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial","volume":"16","author":"Fiander","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.062_bib1275","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03079457.2015.1053840","article-title":"Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime\/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2.1 virus","volume":"44","author":"Kilany","year":"2015","journal-title":"Avian Pathol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.11.062_bib1280","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/infdis\/jiu359","article-title":"Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A (H5N1) vaccine in infants and children < 3 years of age","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.062_bib1285","doi-asserted-by":"crossref","first-page":"e95496","DOI":"10.1371\/journal.pone.0095496","article-title":"Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization","volume":"9","author":"Khurana","year":"2014","journal-title":"PLOS ONE"},{"issue":"20","key":"10.1016\/j.vaccine.2015.11.062_bib1290","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1007\/s00253-015-6697-8","article-title":"DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1","volume":"99","author":"Li","year":"2015","journal-title":"Appl Microbiol Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15017430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15017430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T16:54:34Z","timestamp":1567443274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15017430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0264410X15017430"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}